Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Sep

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Amit Sanyal, MD: A Clinician’s Perspective

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

TMC-I Regimen May Expand Treatment Access in Advanced Head and Neck Cancer

Mobile CT Lung Cancer Screening May Expand Access for Underserved Populations

ASTRO Issues Its First Clinical Guideline on Radiation Therapy for Bladder Cancer

Losing Weight and Breast Cancer Risk? The GLP-1 Question

FDA Approves Imlunestrant in Combination With Abemaciclib for ER-Positive, HER2-Negative, ESR1-Mutated Advanced or Metastatic Breast Cancer